ABBV vs PFE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
PFE has more upside to fair value
(+30.1%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PFE |
| Current Price |
$208.05 |
$26.91 |
| Fair Value Estimate |
$217.50 |
$35.00 |
| Upside to Fair Value |
+4.5%
|
+30.1%
|
| Market Cap |
$367.9B |
$153.0B |
| Forward P/E |
14.9x
|
9.5x
|
| EV / EBITDA |
16.7x
|
13.8x
|
| Price / Sales |
6.1x
|
2.4x
|
| Price / FCF |
20.9x
|
16.8x
|
| Revenue Growth YoY |
+8.6%
|
-1.6%
|
| Gross Margin |
83.7%
|
70.3%
|
| Operating Margin |
34.7%
|
24.7%
|
| Return on Equity |
-129.24%
|
9.0%
|
| Dividend Yield |
3.2% |
6.4% |
| FCF Yield |
4.78%
|
5.9%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
| Metric |
ABBV |
PFE |
| Zone Low |
$163.13 |
$25.00 |
| Zone High |
$184.88 |
$29.00 |
| In Buy Zone? |
No
|
Yes
|